Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...

SEQUENCE, a Phase 3 head-to-head study (study drug open-label and efficacy assessment blinded) compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely ...

The analysis focused on patient-reported outcomes gathered across three phase 3 trials that pitted risankizumab against J&J’s Stelara and AbbVie’s own Humira. A pooled analysis of data from ...

Risankizumab is linked to significantly greater improvements in psoriatic arthritis signs and symptoms than placebo in patients with an inadequate response, or intolerance, to other drugs ...

NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that SKYRIZI ® (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, is now available in the U.S. as a ...

Risankizumab is to be taken by subcutaneous (injected into the fatty layer of skin) route. Patient may self-inject. Dosage & When it is to be taken It is available as Injection: 75 mg/0.83 mL in ...

Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022 Apr 19;e15524. doi:10. ...

Meeting Coverage > AAD Biologic Switch Revs Up Response in Plaque Psoriasis — "Dramatic improvement" at 16 weeks with IL-23 blocker after lack of response to anti-IL-17 drug by Charles Bankhead ...

In the FORTIFY study, results showed that 47% and 52% of patients treated with risankizumab 360mg achieved endoscopic response and clinical remission (as measured by CDAI), respectively, at week ...

AbbVie has developed risankizumab in collaboration with Boehringer Ingelheim and the candidate is also being evaluated in phase III studies in psoriasis, Crohn's disease and psoriatic arthritis.